Effects of the application of erythropoietin on cerebral recovery after cardiac arrest in rats

Resuscitation

Volumn 74, Issue 2, 2007, Pages 344-351

  Popp, Erik ^a   Vogel, Peter ^a   Teschendorf, Peter ^a   Böttiger, Bernd W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Apoptosis; Cardiac arrest; Cardiopulmonary resuscitation (CPR); Erythropoietin; Global cerebral ischaemia; Growth factor

Indexed keywords

CASPASE; ERYTHROPOIETIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DEFIBRILLATION; DRUG EFFECT; ENZYME ACTIVITY; HEART ARREST; HEART VENTRICLE FIBRILLATION; HIPPOCAMPUS; MALE; NERVE CELL DEGENERATION; NEUROPROTECTION; NICK END LABELING; NISSL STAINING; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION; RESUSCITATION;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN ISCHEMIA; CASPASES; ERYTHROPOIETIN; HEART ARREST; IN SITU NICK-END LABELING; INJECTIONS, INTRAVENOUS; MALE; RANDOM ALLOCATION; RATS; RATS, WISTAR; STATISTICS, NONPARAMETRIC;

EID: 34347389645     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2007.01.019     Document Type: Article

References (34)

1. Böttiger B.W., Grabner C., Bauer H., et al. Long term outcome after out-of-hospital cardiac arrest with physician staffed emergency medical services: the Utstein style applied to a midsized urban/suburban area. Heart 82 (1999) 674-679
2. Popp E., Padosch S.A., Vogel P., et al. Effects of intracerebroventricular application of brain-derived neurotrophic factor on cerebral recovery after cardiac arrest in rats. Crit Care Med 32 (2004) S359-S365
3. Vogel P., Putten H., Popp E., et al. Improved resuscitation after cardiac arrest in rats expressing the baculovirus caspase inhibitor protein p35 in central neurons. Anesthesiology 99 (2003) 112-121
4. Brain Resuscitation Clinical Trial I Study Group. Randomized clinical study of thiopental loading in comatose survivors of cardiac arrest. N Engl J Med 314 (1986) 397-403
5. Brain Resuscitation Clinical Trial II Study Group. A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac arrest. N Engl J Med 324 (1991) 1225-1231
6. Ruscher K., Freyer D., Karsch M., et al. Erythropoietin is a paracrine mediator of ischemic tolerance in the brain: evidence from an in vitro model. J Neurosci 22 (2002) 10291-10301
7. Morishita E., Masuda S., Nagao M., Yasuda Y., and Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76 (1997) 105-116
8. Sadamoto Y., Igase K., Sakanaka M., et al. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun 253 (1998) 26-32
9. Calapai G., Marciano M.C., Corica F., et al. Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation. Eur J Pharmacol 401 (2000) 349-356
10. Siren A.L., Fratelli M., Brines M., et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 98 (2001) 4044-4049
11. Bernaudin M., Marti H.H., Roussel S., et al. A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19 (1999) 643-651
12. Ehrenreich H., Hasselblatt M., Dembowski C., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 8 (2002) 495-505
13. Nagai A., Nakagawa E., Choi H., et al. Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 60 (2001) 386-392
14. Ghezzi P., and Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell Death Differ 11 Suppl. 1 (2004) S37-S44
15. Erbayraktar S., Yilmaz O., Gokmen N., and Brines M. Erythropoietin is a multifunctional tissue-protective cytokine. Curr Hematol Rep 2 (2003) 465-470
16. European Communities Council. Council Directive 86/609/EEC of 24 November 1986 on the Approximation of Laws, Regulations and Administrative Provisions of the Member States Regarding the Protection of Animals used for Experimental and other Scientific Purposes. http://europa.eu.int/smartapi/cgi/sga_doc?smartapi!celexapi!prod!CELEXnumdoc&lg=EN&numdoc=31986L0609&model=guichett.
17. Katz L., Ebmeyer U., Safar P., Radovsky A., and Neumar R. Outcome model of asphyxial cardiac arrest in rats. J Cereb Blood Flow Metab 15 (1995) 1032-1039
18. Neumar R.W., Bircher N.G., Sim K.M., et al. Epinephrine and sodium bicarbonate during CPR following asphyxial cardiac arrest in rats. Resuscitation 29 (1995) 249-263
19. Gavrieli Y., Sherman Y., and Ben Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119 (1992) 493-501
20. Ferrer I., Tortosa A., Macaya A., et al. Evidence of nuclear DNA fragmentation following hypoxia-ischemia in the infant rat brain, and transient forebrain ischemia in the adult gerbil. Brain Pathol 4 (1994) 115-122
21. Garcia-Calvo M., Peterson E.P., Leiting B., et al. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 273 (1998) 32608-32613
22. Wright G.L., Hanlon P., Amin K., et al. Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18 (2004) 1031-1033
23. Silva M., Grillot D., Benito A., et al. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 88 (1996) 1576-1582
24. Chong Z.Z., Lin S.H., Kang J.Q., and Maiese K. Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. J Neurosci Res 71 (2003) 659-669
25. Masuda S., Nagao M., Takahata K., et al. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 268 (1993) 11208-11216
26. Cerami A., Brines M., Ghezzi P., Cerami C., and Itri L.M. Neuroprotective properties of epoetin alfa. Nephrol Dial Transplant 17 Suppl. 1 (2002) 8-12
27. Lipsic E., van der Meer P., Henning R.H., et al. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 44 (2004) 473-479
28. Wolf R., Gilmore L., Friese P., et al. Erythropoietin potentiates thrombus development in a canine arterio-venous shunt model. Thromb Haemost 77 (1997) 1020-1024
29. Wun T., Law L., Harvey D., et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 98 (2003) 1514-1520
30. Böttiger B.W., Krumnikl J.J., Gass P., et al. The cerebral 'no-reflow' phenomenon after cardiac arrest in rats-influence of low-flow reperfusion. Resuscitation 34 (1997) 79-87
31. Böttiger B.W., Motsch J., Böhrer H., et al. Activation of blood coagulation after cardiac arrest is not balanced adequately by activation of endogenous fibrinolysis. Circulation 92 (1995) 2572-2578
32. Erbayraktar S., Grasso G., Sfacteria A., et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 100 (2003) 6741-6746
33. Petito C.K., Pulsinelli W.A., Jacobson G., and Plum F. Edema and vascular permeability in cerebral ischemia: comparison between ischemic neuronal damage and infarction. J Neuropathol Exp Neurol 41 (1982) 423-436
34. Brines M.L., Ghezzi P., Keenan S., et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97 (2000) 10526-10531